hotspot -WSS

hotspot

author：knowledge 2025-10-02 20:46:51 - browse：6969

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： IVF, abortion rights issues kick off Biden’s State of the Union

hotspot

WSS

How to fix cancer clinical trials' diversity problem

How generative AI is inspiring dreams of a health data revolution

Ethical issues complicate the benefits of medical crowdfunding

Medicaid rebukes states for mistakenly disenrolling children

The Readout: Amylyx, Alumis, and Lundbeck drug updates

What it’s like to watch children die of measles

hotspot

hotspot

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Amylyx ALS drug failure raises questions and concerns

Jerome Adams on the need for new antivirals for Covid

A new House health package & hospitals’ new site

Continuity nursing helped my family in our darkest PICU moments

What drug price negotiations mean for Medicare Part D

Medical records are filled with copy

Crinetics acromegaly drug succeeds in late

BioMarin wins approval for gene therapy to treat hemophilia A

Novo Nordisk obesity pill bests Wegovy in early trial

focus

Precocious puberty in girls comes with mental health risks

NEJM study link tiny plastics in blood vessels to heart problems

What drug price negotiations mean for Medicare Part D

First medicine developed to treat MASH expected to be approved soon

Listen: Biogen's potential pivot, & Illumina's next chapter

Ethical issues complicate the benefits of medical crowdfunding

leisure time

leisure time

hotspot

knowledge